Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03451149
Other study ID # OHSU eIRB # 16296
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 25, 2017
Est. completion date January 29, 2019

Study information

Verified date November 2023
Source Oregon Health and Science University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A novel radiofrequency (RF) wire created by Baylis Medical (Montreal, CAN) is an FDA cleared device commonly used for percutaneous recanalization procedures. This wire has an active tip that delivers focused RF energy and has been applied for many procedures such as percutaneous transseptal left heart access, recanalization of central vein occlusion, recanalization of arterial occlusion, and recanalization of bile duct occlusion. There has been no study investigating the use of the RF wire for TIPS creation in clinical practice with humans. Having promising results of an experimental feasibility investigation in swine, the investigators are seeking to assess the feasibility and safety of the RF wire to cut through tissue in the liver while creating TIPS in the clinical setting.


Description:

The transjugular intrahepatic portosystemic shunt procedure (TIPS), first described in 1969 by Rösch et al., has been widely used to treat the complications of portal hypertension such as recurrent variceal hemorrhage and refractory ascites. In the TIPS procedure, an intrahepatic connection between a hepatic vein and a portal vein branch is created in order to reduce the portal venous pressure. A dedicated device developed for the TIPS procedure, the Rösch-Uchida Transjugular Liver Access Set (RUPS), is widely used for this procedure. The most challenging and time-consuming part of TIPS creation is puncturing the portal vein from the hepatic vein with a long needle trocar. Occasionally in cirrhotic livers, the trocar needle can deflect and not easily pass through the parenchyma. Needle deflection may lead to additional needle passes and potentially increase risk of inadvertent injury to the liver or extracapsular puncture. There is need, therefore, for a device that can easily penetrate dense liver tissue without creating significant trauma. A novel radiofrequency (RF) wire created by Baylis Medical (Montreal, CAN) is an FDA cleared device commonly used for percutaneous recanalization procedures. This wire has an active tip that delivers focused RF energy and has been applied for many procedures such as percutaneous transseptal left heart access, recanalization of central vein occlusion, recanalization of arterial occlusion, and recanalization of bile duct occlusion. The investigators have assessed the application of the RF wire for TIPS creation in a swine model. The investigators found that the use of this wire to cut through tissue during TIPS creation is feasible in swine with some potential advantages compared with the current available tools. The RF wire device was well visualized under intravascular ultrasound (IVUS) guidance and could penetrate through the liver parenchyma smoothly and safely. In addition, the RF wire was able to subsequently be used as a working wire to complete the procedure. Advantages in clinical practice with cirrhotic livers would be the relative ease of penetration into a hardened liver compared to the trocar needle, and the additional benefit of being able to use the device as a working wire to minimize the risk of catheter displacement and decrease procedure time. There has been no study investigating the use of the RF wire for TIPS creation in clinical practice with humans. Having the promising results of the experimental investigation in swine, the investigators are seeking to assess the feasibility and safety of the RF wire to cut through tissue in the liver while creating TIPS in the clinical setting. It is anticipated that the proposed experimental technique using the RF wire would be at least as safe as the current standard technique. The wire diameter, 0.035 inches, is smaller than the traditionally used 0.038 inch needle trocar, and the deposition of RF energy is limited to the wire tip with minimal collateral damage. Risks of complications, such as puncturing unintended structures including the liver capsule, hepatic artery, gallbladder and biliary tree are anticipated to be at least as low as for the standard technique, estimated at about 3-4%. Moreover, these risks may be reduced even further in the experimental technique owing to the use of intravascular ultrasound guidance, enabling direct visualization of the puncture compared to the standard technique using landmarks and reference images under x-ray fluoroscopy.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date January 29, 2019
Est. primary completion date January 29, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 99 Years
Eligibility Inclusion Criteria: 1. Patients with cirrhosis and portal hypertension meeting at least one indication for elective TIPS creation including refractory ascites, acute variceal bleeding not responsive to endoscopic treatment, prevention of recurrent variceal bleeding, portal hypertensive gastropathy, hepatorenal syndrome, Budd-Chiari syndrome, hepatic hydrothorax, hepatic veno-occlusive disease, and hepatopulmonary syndrome. 2. Patients who agree to undergo TIPS procedure and participate in this clinical study. 3. Age over 20 years Exclusion Criteria: 1. Patients with a contraindication for TIPS including congestive heart failure, severe tricuspid regurgitation, severe pulmonary hypertension, uncontrolled systemic infection or sepsis and unrelieved biliary obstruction. 2. Patients in whom intravascular ultrasound cannot be used because of venous occlusion. 3. Decisionally impaired patients 4. Need for emergent TIPS creation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Radiofrequency wire (Powerwire)
Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.

Locations

Country Name City State
United States OHSU Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
Oregon Health and Science University Baylis Medical Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility to use the device as anticipated Ability of the device to perform as anticipated within 24 hours
Primary Incidence of device-related adverse events (Safety) No device-related adverse events within 24 hours
Secondary Penetrating ability To assess the capability of the RF wire to cut through tissue without significant deflection through parenchyma within 24 hours
Secondary Device use as a standard working wire To assess the capability of the RF wire to act as the working wire for delivery of the TIPS set into the portal vein after access. within 24 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05052892 - A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)
Recruiting NCT05251272 - A Combined Model Based on Spleen Stiffness, Liver Stiffness and Platelets for Assessing Portal Hypertension in Compensated Cirrhosis (CHESS2202)
Recruiting NCT05928624 - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients N/A
Recruiting NCT04578301 - Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Not yet recruiting NCT05515861 - Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices N/A
Recruiting NCT02364297 - TIPS in Fundal Variceal Bleeding (the TFB Study) N/A
Recruiting NCT01358123 - Value of Von Willebrand Factor in Portal Hypertension N/A
Completed NCT00493480 - Danish Carvedilol Study in Portal Hypertension Phase 3
Recruiting NCT06266260 - Evaluation of the Performance of Direct Portal Pressure Measurement by Endoscopic Ultrasound in a Large Cohort of Patients With Advanced Chronic Liver Disease of Different Etiologies and Newly Diagnosed Clinically Significant Portal Hypertension (EVADIPP)
Recruiting NCT03277651 - Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension N/A
Active, not recruiting NCT03736265 - Carvedilol for Prevention of Esophageal Varices Progression N/A
Completed NCT02994485 - Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Phase 4
Completed NCT01851252 - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy Phase 1
Completed NCT01923064 - Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices N/A
Completed NCT01456286 - Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Phase 2/Phase 3
Completed NCT01551966 - Esophageal Capsule Endoscopy in Children N/A
Completed NCT02344719 - Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis Phase 4
Recruiting NCT00414713 - Transfusion Requirements in Gastrointestinal (GI) Bleeding Phase 4
Completed NCT00766805 - Endoscopic Variceal Ligation (EVL)+ Drugs Versus Endoscopic Variceal Ligation (EVL) Alone For Secondary Prophylaxis N/A
Completed NCT04806750 - Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension Phase 2